StimBiotics

 Here is a non-confidential slide deck describing StimBiotics and its antimicrobial platform of dual acting anti-resistance compounds

StimBiotics is a small molecule pharmaceutical company addressing the Very Big problem of multi-drug resistance with a strategy to make MDR bacteria sensitive to antibiotics again.

Antibiotic resistance is an inevitable consequence of exposure to antibiotic therapy, rendering many bacteria resistant to multiple antibiotics in high-risk patients.  We have been losing antibiotics to this “selection pressure” problem faster than our discovery process has replaced them. Although important and successful conventional targets, such as beta lactamase inhibitors, do have benefits, they have also failed to break the selection pressure paradigm. Our new approach is unique, in that it restores and enhances  antibacterial activity across multiple drug classes.

StimBiotics can restore the activity of the currently available antibiotics with a proprietary compound that engenders bacterial apoptotic-like cell death, instead of permitting the pathogen’s survival as an antibiotic-resistant strain. This is the first time we can break the cycle of antibiotic use vs resistance that is the underlying reason we lose all the antibiotics in the first place.

StimBiotics is proposing to address the AMR problem for multiple classes of antibiotics by stimulating the apoptotic pathway when used in combination with existing, and new, antibiotics.

Our StimBiotics compounds have an entirely novel mechanism of action, one that kills A. baumannii (selectively) and have additionally been demonstrated to prevent evolution of resistance to not only itself, but also polymyxins, aminoglycosides, fluoroquinolones, and most beta-lactams.

Key management and Board Members & their brief biographical sketch:

Michael Stevens, PharmD, CEO. Over 30 years of experience in big pharma and small biotech. Served as Vice President, Medical Affairs Virology at Bristol-Myers Squibb and as Chief Strategy Officer for ViroStatics.

Snezna Rogelj, PhD, Chief Scientific Officer. Professor and former Department Chair, Biology at New Mexico Tech. StimBiotics’ products and technology are based on Dr. Rogelj’s research.

Jerome J. Schentag, PharmD, Chief Pharmacology Officer, Emeritus Professor of Pharmaceutical Sciences at the University of Buffalo, NY.  Over 40 years of early R&D and clinical trials experience in anti-infectives, infectious disease, and other therapeutic areas.